Found 1497 with Last Name = 'nilsson' and Initial = 'k' 
Affinity DataKi: 0.0500nM ΔG°: -59.8kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Affinity DataKi: 0.0500nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 0.100nM ΔG°: -58.0kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Affinity DataKi: 0.100nM ΔG°: -58.0kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Affinity DataKi: 0.100nM ΔG°: -58.0kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Affinity DataKi: 0.100nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 0.100nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 0.100nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 0.200nM ΔG°: -56.3kJ/molepH: 7.5 T: 2°CAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 0.25nM ΔG°: -55.7kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Affinity DataKi: 0.25nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 0.300nM ΔG°: -55.3kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Affinity DataKi: 0.300nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 0.5nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 0.5nM ΔG°: -54.0kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
3D Structure (crystal)
Affinity DataKi: 2.40nM ΔG°: -50.0kJ/molepH: 7.5 T: 2°CAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 4.30nM ΔG°: -47.3kJ/mole EC50: 14nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
Affinity DataKi: 5nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 5nM ΔG°: -48.2kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 5.10nM ΔG°: -46.9kJ/mole EC50: 8.64nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
Affinity DataKi: 9.40nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 9.40nM ΔG°: -46.6kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 10nM ΔG°: -45.2kJ/mole EC50: 15nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 14nM ΔG°: -44.4kJ/mole EC50: 23nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 15nM ΔG°: -44.2kJ/mole EC50: 19nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 33nM ΔG°: -42.3kJ/mole EC50: 41nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
Affinity DataKi: 40nM ΔG°: -42.9kJ/molepH: 7.5 T: 2°CAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 43nM ΔG°: -42.8kJ/molepH: 7.5 T: 2°CAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 48nM ΔG°: -41.4kJ/mole EC50: 81nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 50nM ΔG°: -41.3kJ/mole EC50: 130nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 70nM ΔG°: -40.4kJ/mole EC50: 250nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 94nM ΔG°: -39.7kJ/mole EC50: 220nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 180nM ΔG°: -38.1kJ/mole EC50: 150nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 200nM ΔG°: -37.9kJ/mole EC50: 270nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 220nM ΔG°: -37.6kJ/mole EC50: 750nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 480nM ΔG°: -35.7kJ/mole EC50: 1.70E+3nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 840nM ΔG°: -34.3kJ/mole EC50: 600nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
Affinity DataKi: 1.00E+3nM ΔG°: -34.8kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Affinity DataKi: 1.00E+3nM ΔG°: -34.8kJ/molepH: 7.5 T: 2°CAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
Affinity DataKi: 1.07E+3nM ΔG°: -34.6kJ/molepH: 7.5 T: 2°CAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid (GABA) B receptor 1/type B receptor subunit 2 [41-940](Rattus norvegicus (rat))
Astrazeneca
Astrazeneca
Affinity DataKi: 2.10E+3nM ΔG°: -32.1kJ/mole EC50: 1.10E+3nMpH: 7.4 T: 2°CAssay Description:Inhibition of [3H]GABA binding at GABAB receptor sites in rat brain synaptic membranes by test compounds was measured using a filtration binding assa...More data for this Ligand-Target Pair
Affinity DataIC50: 0.850nMAssay Description:Displacement of [3H]-CP55,940 from human CB1 receptor expressed in HEK293S cell membranes by scintillation counting analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 0.970nMAssay Description:Displacement of [3H]-CP55,940 from human CB1 receptor expressed in HEK293S cell membranes by scintillation counting analysisMore data for this Ligand-Target Pair
TargetAlpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of human recombinant MGAT2 expressed in insect cell membrane using 2-oleoyl-sn-glycerol and oleoyl coenzyme A as substrate after 40 mins b...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:Displacement of [3H]-CP55,940 from human CB1 receptor expressed in HEK293S cell membranes by scintillation counting analysisMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
